Artificial intelligence tools based on large language models (LLMs) find it hard to identify genetic conditions based on patient-written descriptions, suggesting there is some way to go bef
Back in the picturesque West End of London, even a sudden, torrential downpour could not dampen the spirits on 12th March as speakers and attendees returned once more to the Hilton Hotel in
Everyone’s talking about AI these days and it can be easy to get lost in the whirlwind of terms, like machine learning, generative AI, large language models, and natural language processing
Generative AI – large language models, or LLMs, like ChatGPT – has the potential to revolutionise almost any knowledge industry, and pharma is no exception.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.